Do CCR5 Antagonists Improve the Overall Survival of Patients With AIDS-related Progressive Multifocal Leucoencephalopathy?

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03969550

Enrollment

Registered

2019-05-31

Start date

2008-01-31

Completion date

2015-12-31

Last updated

2019-05-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AIDS, Progressive Multifocal Leucoencephalopathy (PML)

Keywords

Maraviroc, John Cunningham virus (JCV), Immune reconstitution inflammatory syndrome (IRIS), Combined antiretroviral treatment (cART), Overall survival (OS)

Brief summary

Progressive multifocal leucoencephalopathy (PML) is a demyelinating disease caused by John Cunningham virus (JCV) reactivation. Numerous molecules have been overstated because there were inaccurately tested in non-rigorous clinical trial. The objective is to draw lessons from repeatedly false hopes of unconfirmed PML treatments that might contribute to prescribing ineffective drugs on claimed efficacy in case reports or small series and by failing to respect the need for clinical trial evaluation before authorizing their widespread use.

Interventions

OTHERMeasure of overall survival

Measure of overall survival among AR-PML (AIDS-related PML) patients, exposed or not to maraviroc (MVC), and immune reconstitution inflammatory syndrome (IRIS) onset.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with AR-PML * Diagnosed between January 2008 and December 2015 * Followed in one of the four University Hospitals' Infectious Diseases Departments

Design outcomes

Primary

Measure	Time frame
Overall survival (OS)	8 years

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026